Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer.

Heyns CF, Simonin MP, Grosgurin P, Schall R, Porchet HC

BJU international1 Aug 2003Cited by 65 (Europe PMC)

PMID12887472DOI10.1046/j.1464-410x.2003.04308.xPepBankPUB-12887472

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

01HumanRandomized controlled trialEfficacy outcome
In men with advanced prostate cancer, triptorelin produced a lower day-29 castration rate than leuprolide.
In plain wordsIn men with advanced prostate cancer, triptorelin produced a lower early castration rate than leuprolide.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseCastrate testosterone at day 29
Study
n = 284
Comparator
Leuprolide 7.5 mg
Analysis
Primary
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg · intramuscular · 9 monthsAs given in this study (human).
Measurements
Castration rate
91.2%
triptorelin day 29
Castration rate
99.3%
leuprolide day 29
Difference in castration rate
−8%
triptorelin minus leuprolide, day 29
Source sentences
Summary
The percentage of men with castrate levels of serum testosterone was lower at 29 days for triptorelin than for leuprolide (91.2% vs 99.3%; point estimate - 8.0, 95% confidence interval - 16.9% to - 1.4%), but equivalent at 57 days (97.7% vs 97.1%).
2 context sentences(design, population, supporting numbers)
Summary · context
Men with advanced prostate cancer were randomly assigned to receive triptorelin 3.75 mg or leuprolide 7.5 mg.
Summary · context
The agent was injected intramuscularly every 28 days for nine injections.
Report a problemFND-1288747201
02HumanRandomized controlled trialEfficacy outcome
In men with advanced prostate cancer, day-57 castration rates were equivalent with triptorelin and leuprolide.
In plain wordsIn men with advanced prostate cancer, castration rates were equivalent with triptorelin and leuprolide at the later assessment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeCastrate testosterone at day 57
Study
n = 284
Comparator
Leuprolide 7.5 mg
Analysis
Primary
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg · intramuscular · 9 monthsAs given in this study (human).
Measurements
Castration rate
97.7%
triptorelin day 57
Castration rate
97.1%
leuprolide day 57
Source sentences
Summary
The percentage of men with castrate levels of serum testosterone was lower at 29 days for triptorelin than for leuprolide (91.2% vs 99.3%; point estimate - 8.0, 95% confidence interval - 16.9% to - 1.4%), but equivalent at 57 days (97.7% vs 97.1%).
2 context sentences(design, population, supporting numbers)
Summary · context
Men with advanced prostate cancer were randomly assigned to receive triptorelin 3.75 mg or leuprolide 7.5 mg.
Summary · context
The agent was injected intramuscularly every 28 days for nine injections.
Report a problemFND-1288747202
03HumanRandomized controlled trialEfficacy outcome
In men with advanced prostate cancer, mean castration maintenance rates were equivalent with triptorelin and leuprolide.
In plain wordsIn men with advanced prostate cancer, triptorelin and leuprolide maintained castration at equivalent mean rates.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeMean castration maintenance rate
Study
n = 284
Comparator
Leuprolide 7.5 mg
Analysis
Primary
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg · intramuscular · 9 monthsAs given in this study (human).
Measurements
Mean maintenance rate
98.8%
triptorelin
Mean maintenance rate
97.3%
leuprolide
Source sentences
Summary
The mean (98.8% vs 97.3%) and cumulative (96.2% vs 91.2%) castration maintenance rates between 29 and 253 days were equivalent between the treatment groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Men with advanced prostate cancer were randomly assigned to receive triptorelin 3.75 mg or leuprolide 7.5 mg.
Summary · context
The agent was injected intramuscularly every 28 days for nine injections.
Report a problemFND-1288747203
04HumanRandomized controlled trialEfficacy outcome
In men with advanced prostate cancer, cumulative castration maintenance rates were equivalent with triptorelin and leuprolide.
In plain wordsIn men with advanced prostate cancer, triptorelin and leuprolide maintained castration at equivalent cumulative rates.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeCumulative castration maintenance rate
Study
n = 284
Comparator
Leuprolide 7.5 mg
Analysis
Primary
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg · intramuscular · 9 monthsAs given in this study (human).
Measurements
Cumulative maintenance rate
96.2%
triptorelin
Cumulative maintenance rate
91.2%
leuprolide
Source sentences
Summary
The mean (98.8% vs 97.3%) and cumulative (96.2% vs 91.2%) castration maintenance rates between 29 and 253 days were equivalent between the treatment groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Men with advanced prostate cancer were randomly assigned to receive triptorelin 3.75 mg or leuprolide 7.5 mg.
Summary · context
The agent was injected intramuscularly every 28 days for nine injections.
Report a problemFND-1288747204
05HumanRandomized controlled trialEfficacy outcome
In men with advanced prostate cancer, leuprolide produced a higher castration rate at 29 days than triptorelin.
In plain wordsIn men with advanced prostate cancer, leuprolide produced a higher castration rate at 29 days than triptorelin.
Peptide
Leuprolide
Outcome
IncreaseCastrate testosterone at 29 days
Study
n = 284
Comparator
Triptorelin 3.75 mg
Analysis
Primary
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
7.5 mg every 28 days · intramuscularAs given in this study (human).
Measurements
Castration rate
99.3%
leuprolide
Castration rate
91.2%
triptorelin
Point estimate
−8 percentage points
triptorelin minus leuprolide
95% confidence interval lower bound
−16.9%
triptorelin minus leuprolide
95% confidence interval upper bound
−1.4%
triptorelin minus leuprolide
Source sentences
Summary
The percentage of men with castrate levels of serum testosterone was lower at 29 days for triptorelin than for leuprolide (91.2% vs 99.3%; point estimate - 8.0, 95% confidence interval - 16.9% to - 1.4%), but equivalent at 57 days (97.7% vs 97.1%).
3 context sentences(design, population, supporting numbers)
Summary · context
Primary endpoints were the percentages of men whose serum testosterone concentrations declined to and were maintained at or below castrate levels (</= 1.735 nmol/L or </= 500 ng/L) during 9 months (253 days) of treatment.
Summary · context
Men with advanced prostate cancer were randomly assigned to receive triptorelin 3.75 mg or leuprolide 7.5 mg.
Summary · context
The agent was injected intramuscularly every 28 days for nine injections.
Report a problemFND-1288747208
06HumanRandomized controlled trialEfficacy outcome
In men with advanced prostate cancer, castration rates at 57 days were equivalent with leuprolide and triptorelin.
In plain wordsIn men with advanced prostate cancer, castration rates at 57 days were equivalent with leuprolide and triptorelin.
Peptide
Leuprolide
Outcome
DecreaseCastrate testosterone at 57 days
Study
n = 284
Comparator
Triptorelin 3.75 mg
Analysis
Primary
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
7.5 mg every 28 days · intramuscularAs given in this study (human).
Measurements
Castration rate
97.1%
leuprolide
Castration rate
97.7%
triptorelin
Source sentences
Summary
The percentage of men with castrate levels of serum testosterone was lower at 29 days for triptorelin than for leuprolide (91.2% vs 99.3%; point estimate - 8.0, 95% confidence interval - 16.9% to - 1.4%), but equivalent at 57 days (97.7% vs 97.1%).
3 context sentences(design, population, supporting numbers)
Summary · context
Primary endpoints were the percentages of men whose serum testosterone concentrations declined to and were maintained at or below castrate levels (</= 1.735 nmol/L or </= 500 ng/L) during 9 months (253 days) of treatment.
Summary · context
Men with advanced prostate cancer were randomly assigned to receive triptorelin 3.75 mg or leuprolide 7.5 mg.
Summary · context
The agent was injected intramuscularly every 28 days for nine injections.
Report a problemFND-1288747209
07HumanRandomized controlled trialEfficacy outcome
In men with advanced prostate cancer, mean castration maintenance rates between 29 and 253 days were equivalent with leuprolide and triptorelin.
In plain wordsIn men with advanced prostate cancer, mean castration maintenance rates were equivalent with leuprolide and triptorelin.
Peptide
Leuprolide
Outcome
DecreaseMean castration maintenance rate
Study
n = 284
Comparator
Triptorelin 3.75 mg
Analysis
Primary
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
7.5 mg every 28 days · intramuscular · 9 months (253 days)As given in this study (human).
Measurements
Mean castration maintenance rate
97.3%
leuprolide
Mean castration maintenance rate
98.8%
triptorelin
Source sentences
Summary
The mean (98.8% vs 97.3%) and cumulative (96.2% vs 91.2%) castration maintenance rates between 29 and 253 days were equivalent between the treatment groups.
3 context sentences(design, population, supporting numbers)
Summary · context
Primary endpoints were the percentages of men whose serum testosterone concentrations declined to and were maintained at or below castrate levels (</= 1.735 nmol/L or </= 500 ng/L) during 9 months (253 days) of treatment.
Summary · context
Men with advanced prostate cancer were randomly assigned to receive triptorelin 3.75 mg or leuprolide 7.5 mg.
Summary · context
The agent was injected intramuscularly every 28 days for nine injections.
Report a problemFND-1288747210
08HumanRandomized controlled trialEfficacy outcome
In men with advanced prostate cancer, cumulative castration maintenance rates between 29 and 253 days were equivalent with leuprolide and triptorelin.
In plain wordsIn men with advanced prostate cancer, cumulative castration maintenance rates were equivalent with leuprolide and triptorelin.
Peptide
Leuprolide
Outcome
DecreaseCumulative castration maintenance rate
Study
n = 284
Comparator
Triptorelin 3.75 mg
Analysis
Primary
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
7.5 mg every 28 days · intramuscular · 9 months (253 days)As given in this study (human).
Measurements
Cumulative castration maintenance rate
91.2%
leuprolide
Cumulative castration maintenance rate
96.2%
triptorelin
Source sentences
Summary
The mean (98.8% vs 97.3%) and cumulative (96.2% vs 91.2%) castration maintenance rates between 29 and 253 days were equivalent between the treatment groups.
3 context sentences(design, population, supporting numbers)
Summary · context
Primary endpoints were the percentages of men whose serum testosterone concentrations declined to and were maintained at or below castrate levels (</= 1.735 nmol/L or </= 500 ng/L) during 9 months (253 days) of treatment.
Summary · context
Men with advanced prostate cancer were randomly assigned to receive triptorelin 3.75 mg or leuprolide 7.5 mg.
Summary · context
The agent was injected intramuscularly every 28 days for nine injections.
Report a problemFND-1288747211
09HumanRandomized controlled trialEfficacy outcome
In men with advanced prostate cancer, secondary endpoints other than survival were equivalent between triptorelin and leuprolide.
In plain wordsIn men with advanced prostate cancer, secondary outcomes other than survival were equivalent between triptorelin and leuprolide.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeSecondary endpoints excluding survival
Study
n = 284
Comparator
Leuprolide 7.5 mg
Analysis
Secondary
Outcome group
Overall treatment effect · Whole body
Studied dose
3.75 mg · intramuscular · 9 monthsAs given in this study (human).
Source sentences
Summary
Secondary endpoints were equivalent between treatment groups except for the 9-month survival rate, which was significantly higher for triptorelin than for leuprolide (97.0% vs 90.5%; P = 0.033).
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary endpoints were luteinizing hormone levels, bone pain, prostate specific antigen levels, quality of life, testosterone pharmacodynamics, survival, and safety variables.
Summary · context
Men with advanced prostate cancer were randomly assigned to receive triptorelin 3.75 mg or leuprolide 7.5 mg.
Summary · context
The agent was injected intramuscularly every 28 days for nine injections.
Report a problemFND-1288747205
10HumanRandomized controlled trialEfficacy outcome
In men with advanced prostate cancer, nine-month survival was higher with triptorelin than leuprolide.
In plain wordsIn men with advanced prostate cancer, survival was higher with triptorelin than leuprolide.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseNine-month survival
Study
n = 284
Comparator
Leuprolide 7.5 mg
Analysis
Secondary
Outcome group
Mortality · Whole body
Studied dose
3.75 mg · intramuscular · 9 monthsAs given in this study (human).
Measurements
Survival
97%
triptorelin
Survival
90.5%
leuprolide
Source sentences
Summary
Secondary endpoints were equivalent between treatment groups except for the 9-month survival rate, which was significantly higher for triptorelin than for leuprolide (97.0% vs 90.5%; P = 0.033).
2 context sentences(design, population, supporting numbers)
Summary · context
Men with advanced prostate cancer were randomly assigned to receive triptorelin 3.75 mg or leuprolide 7.5 mg.
Summary · context
The agent was injected intramuscularly every 28 days for nine injections.
Report a problemFND-1288747206
11HumanRandomized controlled trialOther
In men with advanced prostate cancer, secondary endpoints other than survival were equivalent with leuprolide and triptorelin.
In plain wordsIn men with advanced prostate cancer, secondary endpoints other than survival were equivalent with leuprolide and triptorelin.
Peptide
Leuprolide
Outcome
No significant changeSecondary endpoints except survival
Study
n = 284
Comparator
Triptorelin 3.75 mg
Analysis
Secondary
Outcome group
Treatment Outcomes · Whole body
Studied dose
7.5 mg every 28 days · intramuscular · 9 months (253 days)As given in this study (human).
Source sentences
Summary
Secondary endpoints were equivalent between treatment groups except for the 9-month survival rate, which was significantly higher for triptorelin than for leuprolide (97.0% vs 90.5%; P = 0.033).
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary endpoints were luteinizing hormone levels, bone pain, prostate specific antigen levels, quality of life, testosterone pharmacodynamics, survival, and safety variables.
Summary · context
Men with advanced prostate cancer were randomly assigned to receive triptorelin 3.75 mg or leuprolide 7.5 mg.
Summary · context
The agent was injected intramuscularly every 28 days for nine injections.
Report a problemFND-1288747212
12HumanRandomized controlled trialEfficacy outcome
In men with advanced prostate cancer, survival at 9 months was significantly lower with leuprolide than with triptorelin.
In plain wordsIn men with advanced prostate cancer, survival at 9 months was significantly lower with leuprolide than with triptorelin.
Peptide
Leuprolide
Outcome
DecreaseSurvival at 9 months
Study
n = 284
Comparator
Triptorelin 3.75 mg
Analysis
Secondary
Outcome group
Mortality · Cancer
Studied dose
7.5 mg every 28 days · intramuscular · 9 months (253 days)As given in this study (human).
Measurements
Survival rate
90.5%
leuprolide
Survival rate
97%
triptorelin
P value
0.033
between groups
Source sentences
Summary
Secondary endpoints were equivalent between treatment groups except for the 9-month survival rate, which was significantly higher for triptorelin than for leuprolide (97.0% vs 90.5%; P = 0.033).
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary endpoints were luteinizing hormone levels, bone pain, prostate specific antigen levels, quality of life, testosterone pharmacodynamics, survival, and safety variables.
Summary · context
Men with advanced prostate cancer were randomly assigned to receive triptorelin 3.75 mg or leuprolide 7.5 mg.
Summary · context
The agent was injected intramuscularly every 28 days for nine injections.
Report a problemFND-1288747213
13HumanRandomized controlled trialSafety outcome
In men with advanced prostate cancer, triptorelin and leuprolide were both well tolerated.
In plain wordsIn men with advanced prostate cancer, both triptorelin and leuprolide were well tolerated.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableTolerability
Study
n = 284
Comparator
Leuprolide 7.5 mg
Outcome group
Adverse events · Whole body
Studied dose
3.75 mg · intramuscular · 9 monthsAs given in this study (human).
Source sentences
Summary
Both treatments were well tolerated.
2 context sentences(design, population, supporting numbers)
Summary · context
Men with advanced prostate cancer were randomly assigned to receive triptorelin 3.75 mg or leuprolide 7.5 mg.
Summary · context
The agent was injected intramuscularly every 28 days for nine injections.
Report a problemFND-1288747207
14HumanNon-randomized trialSafety outcome
In men with advanced prostate cancer, leuprolide was well tolerated.
In plain wordsIn men with advanced prostate cancer, leuprolide was well tolerated.
Peptide
Leuprolide
Outcome
Not applicableTolerability
Study
n = 144
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
7.5 mg every 28 days · intramuscular · 9 months (253 days)As given in this study (human).
Source sentences
Summary
Both treatments were well tolerated.
2 context sentences(design, population, supporting numbers)
Summary · context
Men with advanced prostate cancer were randomly assigned to receive triptorelin 3.75 mg or leuprolide 7.5 mg.
Summary · context
The agent was injected intramuscularly every 28 days for nine injections.
Report a problemFND-1288747214

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:37 UTC
Study data updated · source update from Europe PMC
Version 2
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.